Boundless Bio, Inc. (BOLD)
2.32
-0.06
(-2.52%)
USD |
NASDAQ |
Nov 20, 16:00
2.32
0.00 (0.00%)
After-Hours: 20:00
Boundless Bio Enterprise Value : -9.281M for Nov. 20, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 20, 2026 | -9.281M |
| November 19, 2026 | -7.895M |
| November 18, 2026 | -7.432M |
| November 17, 2026 | -7.201M |
| November 16, 2026 | -7.201M |
| November 13, 2026 | -5.122M |
| November 12, 2026 | -6.046M |
| November 11, 2026 | -6.046M |
| November 10, 2026 | -6.277M |
| November 09, 2026 | -6.046M |
| November 06, 2026 | -6.046M |
| November 05, 2026 | -7.201M |
| November 04, 2026 | -7.432M |
| November 03, 2026 | -7.895M |
| November 02, 2026 | -6.508M |
| October 30, 2026 | -5.815M |
| October 29, 2026 | -5.584M |
| October 28, 2026 | -5.122M |
| October 27, 2026 | -7.201M |
| October 26, 2026 | -7.201M |
| October 23, 2026 | -8.357M |
| October 22, 2026 | -6.508M |
| October 21, 2026 | -6.508M |
| October 20, 2026 | -6.739M |
| October 19, 2026 | -9.512M |
| Date | Value |
|---|---|
| October 16, 2026 | -8.819M |
| October 15, 2026 | -8.588M |
| October 14, 2026 | -7.664M |
| October 13, 2026 | -6.739M |
| October 12, 2026 | -3.966M |
| October 09, 2026 | -4.428M |
| October 08, 2026 | -3.273M |
| October 07, 2026 | -1.886M |
| October 06, 2026 | -3.504M |
| October 05, 2026 | -2.811M |
| October 02, 2026 | -2.348M |
| October 01, 2026 | -3.042M |
| September 30, 2026 | -4.890M |
| September 29, 2026 | -15.09M |
| September 28, 2026 | -13.97M |
| September 25, 2026 | -12.84M |
| September 24, 2026 | -14.19M |
| September 23, 2026 | -11.94M |
| September 22, 2026 | -7.898M |
| September 21, 2026 | -9.022M |
| September 18, 2026 | -9.471M |
| September 17, 2026 | -9.696M |
| September 16, 2026 | -9.246M |
| September 15, 2026 | -9.471M |
| September 14, 2026 | -8.797M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.052B |
| Alnylam Pharmaceuticals, Inc. | 18.66B |
| Anika Therapeutics, Inc. | 158.39M |
| Savara, Inc. | 776.30M |
| Arrowhead Pharmaceuticals, Inc. | 6.053B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.364M |
| Total Expenses (Quarterly) | 5.364M |
| EPS Diluted (Quarterly) | -0.2346 |
| Earnings Yield | -106.5% |
| Normalized Earnings Yield | -106.47 |